6 курс / Кардиология / Хроническая_сердечная_недостаточность_1
.pdf
|
|
|
|
|
II |
|
|
|
) |
|
|
) , - |
|
|
III-IV |
|
|
, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
, 2001.
,
*
|
|
|
|
|
, |
) |
|
|
|
|
, |
) |
|
|
|
1 |
|
|
, |
, |
|
) |
|
|
|
|
|
) |
, ) - |
|
( ) |
|
|
, |
|
|
|
|
|
*
, 2001.
,
(I)
|
|
|
|
|
|
|
|
, |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
REACH-1 (1999) |
. |
|
-1: |
|
RITZ-1(2001) |
|
|
( - |
|
RITZ-2(2001) |
|
|
) |
|
ENCOR(2001) |
(REACH-1.ENCOR) |
|
( - |
|
HEAT (2001) |
|
|
- ) |
|
|
|
|
|
|
IMPRESS (2000) |
|
- |
: |
|
|
47% |
|
|
|
|
/ |
|
- |
|
|
|
|
, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
, |
|
|
) |
|
|
|
|
|
|
|
|
RENAISSANSE |
|
|
K TNF - 2- |
|
(2001) |
, |
|
|
|
RECOVER (2001) |
, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
,
(II)
|
|
|
|
|
|
|
|
|
|
|
, |
( ) |
|
|
|
|
|
|
|
|
2+- |
• - |
- |
RUSSLAN(1999) |
|
||
- |
- |
|
LIDO (2000) |
, - |
||
|
- |
|
|
6- - |
||
|
2+; |
|
|
|
||
|
• |
|
|
|
||
|
|
- |
|
|
|
|
|
|
2+ - |
|
|
(RUSSLAN) |
|
|
|
|
|
|
(LIDO) |
|
|
|
; |
|
|
|
|
|
|
• - |
|
|
|
|
|
|
+ |
|
|
|
|
- |
|
|
MOXCON(1999) |
- |
||
|
|
|
|
- |
||
|
|
|
|
- |
||
- |
- |
|
|
, |
||
|
|
|
|
- |
||
|
- |
|
|
- |
||
|
|
|
|
- |
||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
,
*
|
|
|
|
|
|
||||
|
|
|
( ) |
|
|
|
|
( ) |
|
|
|
|
• |
|
2+- - |
2+ |
|
|
|
- |
|
|
• |
|
|
|
|
, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DPI 201-106 |
• |
|
Na+ |
2+ |
BDF9148 |
|
|
|
|
|
||
|
|
|
• |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 ( ) |
|
|
- |
|
• |
|
|
- |
|
2-6 |
|
|
|
|
( , |
|
|
|
|
) |
|
|
|
|
• |
|
|
|
|
|
|
|
|
|
) |
|
( )
:
- |
, |
|
, |
|
|
|
|
|
|
|
|
MUSTIC |
58 III-IV , |
• 23 % |
(2001) |
- |
• 32% |
|
; |
• |
|
6 . |
3 |
|
|
|
MIRACLE |
266 III-IV , |
• , |
(2001) |
- |
|
|
; |
• |
|
6 . |
• , |
|
|
|
PATH-CHF |
42 III - IV ; |
• |
(2000) |
12 . |
• |
|
|
• |
|
|
• 12 . - 97 % (41 42- ) |
|
|
|
CONTAK-CD |
490 II-IV , |
• 23 % |
(2001) |
< 35%, |
• 26 % |
|
, - |
• |
|
- |
9% |
|
|
• |
|
|
|
:
, |
|
|
|
|
, |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
REMATCH |
129 IV , |
Thoratec |
1 : |
(2002) |
< 25% MVO2* < 12 |
|
- 75%, |
|
/ / , |
|
- 48% |
|
- |
|
|
|
, |
|
2- : |
|
|
|
- 92%, |
|
; |
|
- 77% |
|
2 |
|
|
|
|
|
|
INNOVAT |
IV , |
Novacor |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
* MVO2 -
) IV .
5- - 70-80%*.
* J. Heart Lung Transplant., 1999, v. 18, p. 611-626.
( < 50
> 250 )
> 15 . .,
> 60 )
,
1..
:
// . - 1995.- 4.- .78-84.
2.., ., .
:
? // .- 2000.- 4.- . 1-6.
3.., ., .
: ,
/ , .-1999.-128 .
4..
// Doctor-2001 .-N 4(8).- .12-18.
5.., ., ., .
.
. - , 1999, 270 .
6.., .
. I.
// . .-
1.- .- 1.- . 69-74.
7.., .
:
. / ., 1993. - 78 .
8.. , ., .
/ ., , 1994. -624.
9..
// . .-
1.- .- 1.- .5-16.
10..
: . - 1996.- 12.- . 4 - 12.
11.. ,
/ ., , 1978. - 343 .
12.., ., ..
:
, , (
) //
. .-2001 .- .- 1.- . 28 - 33.
.
:
// Doctor-2001 .-N 4 (8).- .52-55.
14.. //
.-1997.- .- 2.- .241-254.
15./ AHA Guidelines for the Evaluation and Management of Chronic Heart Failure in the Adult. A report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines. 2001, by the American College of